- Home
- MARA vs CELC Comparison
MARA vs CELC Comparison
Compare MARA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MARA | CELC |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MARA | CELC |
|---|---|---|
| Price | $10.62 | $118.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $17.85 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 39.9M | 654.3K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $907,093,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.31 | $720.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 38.20 | N/A |
| 52 Week Low | $6.66 | $9.64 |
| 52 Week High | $23.45 | $129.09 |
Technical Indicators
Market Signals| Indicator | MARA | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 50.85 |
| Support Level | $9.34 | $99.38 |
| Resistance Level | $11.57 | N/A |
| Average True Range (ATR) | 0.71 | 7.17 |
| MACD | -0.04 | -0.44 |
| Stochastic Oscillator | 47.37 | 54.80 |
Price Performance
Historical ComparisonAbout MARA Marathon Digital Holdings Inc.
MARA Holdings Inc leverages digital asset computing to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for Bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.